Chimeric Antigen Receptor T Therapy for Adult B-Cell Acute Lymphoblastic Leukemia: State-of the-(C)ART and Road Ahead.

Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy has recently been added to the armamentarium in the battle against B-ALL. In the current review, we discuss the trials that led to FDA approval of CAR T therapies in patients with B-ALL. We evaluate the evolving role of allogeneic hematopoietic stem cell transplantation in the CAR T era, and discuss lessons learned from the first steps with CAR T in ALL. Upcoming innovations in CAR technology are presented, including combined and alternative targets and off-the-shelf allogeneic CAR T cell strategies. Finally, we envision the role that CAR T could take in the management of adult patients with B-ALL in the near future.